Highlight
– Iron deficiency affects over half of patients with heart failure with preserved ejection fraction (HFpEF), impacting exercise capacity and survival.
– The IRONMET-HFpEF randomized controlled trial tested intravenous ferric derisomaltose (FDI) versus placebo for improving peak oxygen uptake.
– FDI significantly increased peak oxygen consumption by 1.1 mL·kg-1·min-1 at 12 weeks compared to placebo, along with improvements in other functional parameters.
– No serious adverse events related to FDI were observed, supporting the safety and efficacy of iron repletion in this patient population.


